BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roehrs TA, Auciello J, Tseng J, Whiteside G. Current and potential pharmacological treatment options for insomnia in patients with alcohol use disorder in recovery. Neuropsychopharmacol Rep 2020;40:211-23. [PMID: 32543111 DOI: 10.1002/npr2.12117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Sharma R, Sahota P, Thakkar MM. Rats exposed to chronic alcohol display protracted insomnia and daytime sleepiness-like behavior during alcohol withdrawal. Physiol Behav 2021;228:113200. [PMID: 33038349 DOI: 10.1016/j.physbeh.2020.113200] [Reference Citation Analysis]
2 Greenwald MK, Moses TEH, Roehrs TA. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities. Transl Res 2021;234:58-73. [PMID: 33711513 DOI: 10.1016/j.trsl.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Roehrs TA, Auciello J, Tseng J, Whiteside G. Current and potential pharmacological treatment options for insomnia in patients with alcohol use disorder in recovery. Neuropsychopharmacol Rep 2020;40:211-23. [PMID: 32543111 DOI: 10.1002/npr2.12117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 2021;183:108359. [PMID: 33091458 DOI: 10.1016/j.neuropharm.2020.108359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]